Chime Biologics, a leading global CDMO that enables its partners' success in biologics, and Waterstone, a reliable partner ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster ...

Secures $3.2m in PIPE Financing -- $50m Term Sheet Obtained for Available Financing under Equity Line of Credit - BOSTON and ...

Entero has signed a binding term sheet in which private biotech Journey is slated to acquire 99% of Entero’s equity, ...

Swiss CDMO Lonza is bulking up its bioconjugation manufacturing digs with two new multicustomer suites and 200 new jobs at ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

Araris Biotech is a pioneering leader in the development of antibody-drug conjugates (ADCs) with the potential for unparalleled efficacy and tolerability. The Araris ADC technology AraLinQ™ enables ...

Press Release: Araris Biotech Publishes Foundational Science Behind its Novel Antibody-Drug Conjugate Platform in ChemBioChem First characterization of its novel conjugation technology for creating ...

Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel ...

NextCure is going all in on its preclinical B7-H4-directed antibody-drug conjugate (ADC). | NextCure is going all in on its ...

A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...

Leerink Partners analyst Jeffrey La Rosa has maintained their bullish stance on PYXS stock, giving a Buy rating yesterday. Jeffrey La Rosa has ...